Why the study?
Bleeding complications after TAVI negatively affect survival, but the rate and impact of protamine sulfate administration on bleeding complications remain unclear.
Does protamine sulfate administration reduce major bleeding in patients undergoing transfemoral TAVI?
Does protamine sulfate administration reduce major bleeding in patients undergoing transfemoral TAVI?
In this preliminary observational assessment, protamine sulfate administration during transfemoral TAVI did not decrease the rate of major bleeding complications.
PS administration was not associated with reduced major bleeding after TAVI; leaves open whether routine reversal improves outcomes.
INTRODUCTION: Bleeding complications after transcatheter aortic valve implantation (TAVI) are an important issue and negatively affect survival. The rate and impact of protamine sulfate (PS) administration on bleeding complications after TAVI remain unclear. AIM: To assess the impact of PS on bleeding complications after TAVI. MATERIAL AND METHODS: Between March 2010 and November 2016 two hundred fifty-eight patients qualified for TAVI in one academic center were screened. Baseline, procedural and follow-up data up to 30 days were collected and analyzed. The primary endpoint (PE) was major bleeding according to the Valve Academic Research Consortium up to 48 h after the procedure. RESULTS: = 0.02) predicted the occurrence of a composite of major and minor bleeding. CONCLUSIONS: In this analysis, PS administration did not decrease the PE rate. Female gender predicted PE occurrence. Randomized, placebo-controlled trials are required to accurately assess the impact of PS.
No takes yet. Share an insight, caveat, or question.
Zbroński et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: